IQOS Vape: Heated Tobacco Products Explained

What IQOS Actually Is

IQOS is not a vape. Philip Morris International built it to heat real tobacco sticks rather than vaporize liquid, which is a genuine technical distinction, and one that still doesn’t make the product safe or non-addictive.

The device heats specially designed tobacco sticks, called HEETS, to between 250-350°C (482-662°F). Conventional cigarettes combust at over 800°C (1472°F). You still inhale nicotine. You are still addicted afterward.

PMI markets the device under a name widely interpreted as “I Quit Ordinary Smoking,” positioning it as a smoke-free alternative for adult smokers. By 2023, PMI reported over 27 million adult users of IQOS and similar heated tobacco products across 71 countries. That scale makes honest evaluation matter.

How IQOS Heats Tobacco

The heat-not-burn mechanism is IQOS’s entire premise. A ceramic blade inside the holder warms the HEETS tobacco stick to the target temperature range, releasing nicotine and flavor compounds from real tobacco without ignition.

The system has three components: the holder with the heating blade, a pocket charger, and the HEETS sticks. One charge powers one session.

Combustion is absent. Some harmful byproducts that come from burning tobacco are measurably reduced. The aerosol you inhale is not clean air.

IQOS vs. Cigarettes vs. Conventional Vapes

In 2020, the FDA authorized IQOS in the U.S. as a Modified Risk Tobacco Product with a “reduced exposure” claim. The authorization specifically noted that completely switching from cigarettes to IQOS significantly reduces your body’s exposure to 15 designated harmful chemicals. No conventional vape has received equivalent FDA authorization.

Feature	IQOS	Cigarette	Conventional Vape
Uses real tobacco	Yes	Yes	No
Combustion	No	Yes	No
Nicotine delivery	Yes	Yes	Yes
FDA MRTP authorization	Yes (reduced exposure)	No	No
Tar production	Minimal	High	None
Carbon monoxide	Reduced	High	Trace
Long-term safety data	Limited	Extensive (grim)	Limited
Addictive	Yes	Yes	Yes

PMI’s own studies show reduced levels of many toxicants compared to cigarette smoke. Independent researchers have confirmed some reductions while also identifying compounds in IQOS aerosol not present in cigarette smoke at all. That asymmetry is the honest summary of what the research shows.

For more on where vapes and HTPs land on the health damage spectrum, see Is Vaping Safer Than Cigarettes?

The Health Research: Real Reductions, Real Limits

Reduced exposure is not the same as reduced harm. The FDA’s authorization documents are precise on this point: lower chemical levels in aerosol don’t automatically translate to lower disease rates decades out. Long-term clinical outcome data for IQOS users doesn’t exist yet.

What we do know: IQOS aerosol contains nicotine, carbonyl compounds, volatile organic compounds, and particulate matter. Levels of several toxicants are lower than in cigarette smoke. Nicotine content is roughly equivalent to cigarettes, which means addiction potential is not reduced.

Derek Lawson, 54, smoked for three decades and switched to IQOS in 2021. His pulmonologist documented improved airway function and lower carbon monoxide readings after six months of consistent switching.

Derek’s own summary: “I’m still hooked. I just smell better.” That’s the honest range of what IQOS delivers.

The Harm Reduction Debate

The public health case for IQOS comes down to a real tension. Harm reduction advocates argue that adult smokers who genuinely cannot quit are better served by a product with fewer combustion byproducts than by continued cigarette use. Complete cessation advocates argue that “better than cigarettes” sustains the addiction rather than addressing it.

Both positions have merit. The complicating factor is that IQOS isn’t only reaching committed smokers. Flavored HEETS variants, hardware aesthetics, and social media presence follow the same recruitment playbooks documented in teen nicotine targeting that the cigarette industry pioneered.

Regulatory responses reflect the same tension. Some governments have approved IQOS as a harm reduction tool for adult smokers. Others have banned it outright, arguing that population-level benefit is unproven and addiction risk is certain.

IQOS Is Not a Cessation Device

PMI doesn’t market IQOS as a quit aid, and it’s not approved as one. Switching to IQOS is a product substitution, not quitting.

Evidence-based cessation options include nicotine replacement therapies like the patch, gum, and lozenge, plus prescription medications like varenicline and bupropion. Those are built to reduce dependence. IQOS sustains it.

If you’re using IQOS as a bridge strategy toward full cessation, that conversation belongs with a physician who can evaluate your quit history and current health. The withdrawal timeline and what it actually feels like day by day is here.

The Bottom Line

IQOS has measurable differences from cigarettes, confirmed by regulatory review. It is not safe. It is not a path off nicotine. The FDA’s reduced exposure designation means exactly what it says: certain chemical levels are lower under controlled conditions. It is not a health endorsement.

If you’re using IQOS, the honest question is what your actual goal is. Reducing some combustion-related chemical exposure is a limited but real benefit for committed smokers who won’t quit otherwise. Getting off nicotine entirely is a different, and more achievable, target than most people expect. Proven strategies to quit all nicotine products start here.